Twelve ex-Commissioners of the US FDA express grave concerns over agency's vaccine policy shift, according to NEJM

NEW YORK, Dec 3 (Reuters) - A group of twelve former U.S. Food and Drug Administration commissioners expressed serious concern on Wednesday regarding proposed modifications to vaccine regulations by the agencys chief scientific officer. Their worry also extends to his claim that COVID-19 vaccines were linked to the deaths of ten children.

The commissioners were responding to a recent email from Vinay Prasad, FDA chief medical and scientific officer, sent to agency staff last week. In it, Prasad suggested that COVID-19 vaccinations may have contributed to the deaths of at least ten children from heart inflammation but provided minimal information about the methodology behind these conclusions. Additionally, he outlined plans to revise vaccine regulations, including those for annual flu shots, emphasizing that companies should demonstrate vaccine effectiveness through randomized trials rather than studies showing immune response alone.

"These proposed guidelines would fundamentally alter vaccine oversight based on selective interpretation of evidence and through a process that sharply departs from the standards that have underpinned the FDAs internationally respected scientific credibility," wrote the former commissioners in the New England Journal of Medicine. The authors include Scott Gottlieb and Brett Giroir, who served as FDA commissioners during the final term of President Donald Trump.

According to the former leaders, Prasads memo "did not clarify the methods or analyses used to reach these retrospective conclusions, nor explain why they justify a comprehensive rewrite of vaccine regulations."

Prasad was appointed by Health Secretary Robert F. Kennedy Jr., a long-standing critic of vaccines who has previously advocated for placebo-controlled trials. Many experts note that such trials are generally considered ethically unfeasible.

Analysis: Concerns Over FDA's Proposed Changes to Vaccine Regulations

The recent concerns raised by twelve former U.S. Food and Drug Administration (FDA) commissioners about proposed changes to vaccine regulations highlight significant issues in the agency’s decision-making process. The commissioners, including former FDA heads Scott Gottlieb and Brett Giroir, expressed deep unease over the statements made by Vinay Prasad, the FDA's chief medical and scientific officer. These concerns primarily focus on his unsubstantiated claim that COVID-19 vaccines were linked to the deaths of ten children due to heart inflammation, which was cited without detailed scientific methodology or transparency.

Prasad's suggestions to revise vaccine regulations — specifically those related to flu shots and COVID-19 vaccines — have raised alarms within the scientific community. His proposal for companies to demonstrate vaccine effectiveness via randomized trials, rather than merely showing immune response through studies, is viewed by many as a significant departure from established standards. Critics argue that these changes could undermine the credibility of the FDA, an institution known for its rigorous scientific processes.

One of the major points of contention is the lack of clarity in Prasad’s memo, which did not explain the analytical methods behind the conclusions or the need for sweeping regulatory changes. The memo's failure to provide solid evidence has made it difficult for experts to evaluate the scientific basis of these proposals. The suggestion to alter vaccine guidelines based on selective interpretations of data only adds to the uncertainty.

These developments come at a time when the FDA's scientific integrity is under intense scrutiny. Appointed by Health Secretary Robert F. Kennedy Jr., a vocal vaccine critic, Prasad’s leadership is increasingly being questioned. While there is a push for more transparency and rigorous data in vaccine safety, many experts believe that the proposed changes could have detrimental consequences for public health and the trust placed in regulatory bodies like the FDA.

The outcome of this debate will likely shape the future of vaccine oversight in the U.S. and influence how vaccine safety and efficacy are communicated to the public.

Sources:

• Twelve former US FDA commissioners deeply concerned about agency's vaccine change, NEJM says

Author: Grace Ellison
Grace Ellison is a journalist focusing on environmental issues and sustainability. She has experience publishing international reports and participating in documentary projects.